O2 BOOT

K971507 · Gwr Medical, Llp · KPJ · Nov 7, 1997 · General, Plastic Surgery

Device Facts

Record IDK971507
Device NameO2 BOOT
ApplicantGwr Medical, Llp
Product CodeKPJ · General, Plastic Surgery
Decision DateNov 7, 1997
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.5650
Device ClassClass 2
AttributesTherapeutic

Intended Use

The intended use of the O2 Boot™ is to provide hyperbaric oxygen to open, chronic wounds as an adjunct therapy in wound management and treatment. Increasing the oxygen concentration above chronic open wounds with the use of this topical hyperbaric oxygen device, may promote the rate of healing and suppress bacterial growth.

Device Story

O2 Boot™ is a topical hyperbaric oxygen chamber for extremities; consists of flexible plastic film boot; features adhesive-backed fabric for patient securement; includes two tubes for oxygen delivery and pressure relief valve to maintain inflation pressure. Device encapsulates whole leg or arm; treats multiple wounds simultaneously in diabetic or geriatric patients. Single-use, disposable design prevents cross-contamination. Operated by healthcare providers in clinical settings; delivers oxygen to open, chronic wounds to promote healing and suppress bacterial growth.

Clinical Evidence

Bench testing only. Physical properties of materials tested per ASTM standards; biocompatibility tested per ISO methods.

Technological Characteristics

Flexible plastic film boot; acrylic adhesive-backed fabric for attachment; integrated oxygen supply and pressure relief tubing. Single-use disposable. Biocompatibility per ISO standards; physical properties per ASTM standards.

Indications for Use

Indicated for patients with skin ulcerations due to diabetes, venous stasis, post-surgical infections, gangrenous lesions, decubitus ulcers, amputations/infected stumps, skin grafts, burns, and frostbite.

Regulatory Classification

Identification

A topical oxygen chamber for extremities is a device that is intended to surround a patient's limb and apply humidified oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers such as bedsores.

Special Controls

*Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance: Topical Oxygen Chamber for Extremities.” See § 878.1(e) for the availability of this guidance document.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K971507 l 04 # Summary of Safety and Effectiveness Joseph R. Westwood Submitter Vice President of Technology GWR Medical, L.L.P. 124 Commons Court Chadds Ford, Pennsylvania 19317 Phone: 610-558-6000 Fax: 610-558-1280 #### Date summary was prepared: April 25, 1997 ## Name(s) of the device: O2 Boot™ ## Identification of predicate device(s) The following are identified as predicate device to the O2 Boot™: OXYCURE™ Cushion. K831825 OXYCURE™ Boot. K840817 Topical Hyperbaric Oxygen Chamber. K861593 Topical Sacral Hyperbaric Oxygen Chamber. K920948 #### Description of the device The GWR O2 Boot™ is a Topical Oxygen Chamber for Extremities. It is composed of a flexible plastic film shaped into a large boot. At the open end of the device there is a layer of white fabric impregnated with an acrylic adhesive and is used to secure the boot to the patient being treated. There are two tubes that pass through the film; one is to inject the O2 and the other contains a pressure relief valve that is set to maintain the proper pressure to inflate the boot, yet not over inflate the boot for treatment of the patient. In addition, plastic tubes are a part of the device and are used to transport the O2 from the O2 supply to the boot and create the oxygen chamber. {1}------------------------------------------------ 1000 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 K971507 ﻟﻢ 05 The O2 Boot™ is designed to encapsulate the whole leg or arm and therefore treat multiple wounds that could be present on the leg in diabetic or geriatric patients. In addition, it is a single use, single patient, disposable device. # GWR Premarket Submission {2}------------------------------------------------ 07 GWR 510(k) Premarket Notification - O2 Boot™ ## Intended Use The intended use of the O2 Boot™ is to provide hyperbaric oxygen to open, chronic wounds as an adjunct therapy in wound management and treatment. Increasing the oxygen concentration above chronic open wounds with the use of this topical hyperbaric oxygen device, may promote the rate of healing and suppress bacterial growth. ## Comparison of device characteristics to predicate The GWR O, Boot™ has the same technical characteristics as the predicate devices. It is almost exactly like the OXYCURE™ Boot marketed by Hospitak, Inc. The other predicates all have similar characteristics in that they are intended to deliver hyperbaric oxygen to open, chronic wounds in oxygen chambers for extremities. The method of delivery, indications for use and the device design is the same for the predicates and the O2 Boot™. The difference between the devices is that the O2 Boot™ is a single-use disposable device and the predicates are multiple use. The single-use characteristics eliminates the problem of disease from one patient to another or from one wound on the same patient to a new wound. The only reusable part is the tubing and it does not come in contact with the patient. #### Non clinical testing The physical properties of the materials used to manufacture the O2 Boot are tested by the suppliers to ensure they meet the specifications for the finished device. The testing are those established by ASTM. The materials that come in contact with the body are also tested using ISO methods for biocompatibility. All of the materials meet the specifications for the device. This is certified by the supplier of the materials to GWR Medical, L.L.P. #### Conclusion It can be concluded based on the information provided that the GWR O2 Boot is substantially equivalent to the predicate devices cited with respect to the indication for use, device design, mechanism of action and labeling. {3}------------------------------------------------ Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of a human figure, with the head, torso, and legs represented by curved lines. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 **NOV - 7 1997** Mr. Joseph R. Westwood V.P. Technology GWR Medical, L.L.P. 124 Commons Court Chadds Ford, Pennsylvania 19317 Re: K971507 Trade Name: O2Boot™ Regulatory Class: III Product Code: KPJ Dated: August 8, 1997 Received: August 14, 1997 Dear Mr. Westwood: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements , as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {4}------------------------------------------------ Page 2 - Mr. Joseph R. Westwood This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, Sincerely yours, - Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ GWR 510(k) Premarket Notification - O2) # Indications for use 941507 510(k) Number None assigned as of this time # Device Name O2Boot™ # Indications for Use Indications for the O-Boot are 1) skin ulcerations due to diabetes, venous stasis, post surgical infections and gangrenous lesions, 2) decubitus ulcers 3) amputations/infected stumps 4) skin grafts 5) burns 6) frostbite. Concurrence of CDRH, Office of Device Evaluation (ODE) - Prescription Use (per 21 CFR 801.109) - □ Over-the Counter Use scotlfo General Restorative GWR Premarket Submission
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...